Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B. McInnes(University of Glasgow), Joachim Sieper(Charité - Universitätsmedizin Berlin), Jürgen Braun(Rheumazentrum Ruhrgebiet), Paul Emery(NIHR Leeds Musculoskeletal Biomedical Research Unit), Désirée van der Heijde(Leiden University Medical Center), John D. Isaacs(Newcastle University), P Georg Dahmen, J. Wollenhaupt(Schön Klinik Hamburg Eilbek), Hendrik Schulze‐Koops(LMU Klinikum), Joseph Kogan(Novartis (Switzerland)), Shenglin Ma(Novartis (China)), M. Schumacher(Novartis Institutes for BioMedical Research), Arthur P. Bertolino(Novartis Institutes for BioMedical Research), Wolfgang Hueber(Novartis (Switzerland)), Paul P. Tak(GlaxoSmithKline (United Kingdom))
Cited by 340
Abstract
Related Papers
No related papers found
Powered by citation graph analysis